VERTEX PHARMACEUTICALS INC

Vertex Pharmaceuticals Incorporated (NASDAQ: VERX) is a global biotechnology company focused on discovering, developing, and commercializing transformative medicines for people with serious diseases, with particular emphasis on specialty markets. The company's website is www.vrtx.com.

Vertex operates across multiple therapeutic areas with an established portfolio of approved medicines and an extensive clinical pipeline. In cystic fibrosis, the company markets five CFTR modulators including ALYFTREK, TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which are used by approximately three-quarters of CF patients in major markets. For hemoglobinopathies, Vertex offers CASGEVY, an ex-vivo CRISPR/Cas9-based gene-editing therapy approved for severe sickle cell disease and transfusion-dependent beta thalassemia. The company also markets JOURNAVX, a first-in-class oral pain signal inhibitor approved in 2025 for moderate-to-severe acute pain in adults.

The company's mid- and late-stage clinical pipeline includes five pivotal programs spanning multiple disease areas. Povetacicept, a dual BAFF and APRIL inhibitor, is in Phase 3 development for IgA nephropathy and primary membranous nephropathy, with regulatory submissions underway. Inaxaplin, a small molecule APOL1 inhibitor, is in Phase 2/3 development for APOL1-mediated kidney disease. Suzetrigine, a selective NaV1.8 pain signal inhibitor, is being evaluated in two Phase 3 trials for diabetic peripheral neuropathy. Zimislecel, an allogeneic stem cell-derived islet cell therapy, completed enrollment in Phase 1/2/3 trials for type 1 diabetes. Additionally, VX-670, an oligonucleotide therapeutic, is in Phase 1/2 development for myotonic dystrophy type 1.

Vertex's strategy emphasizes serial innovation, combining internal research with strategic acquisitions and collaborations. Notable acquisitions include Alpine Immune Sciences for povetacicept development and Semma Therapeutics for the T1D program. The company collaborates with CRISPR Therapeutics on gene-editing therapies, Moderna on mRNA therapeutics for cystic fibrosis, and Entrada Therapeutics on intracellular delivery technologies. Vertex maintains a strong intellectual property portfolio with multiple issued patents protecting its marketed products and pipeline candidates across major markets globally.